Clinical Trial Update: Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab after weekly paclitaxel in platinum-resistant ovarian, fallopian tube, or peritoneal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University College, London | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: UNKNOWN